| Nov 6 |
Outlook Therapeutics® to Present at the Guggenheim Healthcare Innovation Conference
|
| Oct 17 |
Outlook Therapeutics® Participates in a Virtual Investor CEO Connect Segment
|
| Sep 16 |
Outlook Therapeutics® to Participate in the Virtual Investor Closing Bell Series
|
| Sep 13 |
Outlook Therapeutics® Participates in the 2nd Annual Chardan Virtual Ophthalmology Conference Series
|
| Sep 4 |
Outlook Therapeutics® Announces Completion of Enrollment in NORSE EIGHT Clinical Trial
|
| Sep 3 |
Outlook Therapeutics® to Present at the H.C. Wainwright 26th Annual Global Investment Conference
|
| Aug 26 |
Outlook Therapeutics: Poised To Jump With Wet AMD Treatment If It Can Overcome FDA Hurdles
|
| Aug 15 |
Q3 2024 Outlook Therapeutics Inc Earnings Call
|
| Aug 14 |
Outlook Therapeutics, Inc. (OTLK) Q3 2024 Earnings Call Transcript
|
| Aug 14 |
Outlook Therapeutics Non-GAAP EPS of -$0.83 beats by $0.01
|
